# Letrozole

## Femara 2.5mg

##### 

| TAH Drug Code      | [OFEM](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OFEM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of advanced breast cancer in women with natural or artificially induced postmenopausal status, who have previously been treated with antioestrogens. 1st-line treatment in postmenopausal women with hormone-dependent advanced breast cancer. Extended adjuvant treatment of hormone receptor +ve & LN metastasis +ve breast cancer patient who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor +ve invasive early breast cancer.                                                                                                                                                   |
| Dosing             | 2.5 mg orally once a day, without regard to meals for a planned duration of 5 years; discontinue at relapse, disease progression or unacceptable toxicity. In patients with advanced disease, treatment with Femara should continue until tumor progression is evident.                                                                                                                                                                                                                                                                                                                                                                                                  |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| Contraindications  | Hypersensitivity to letrozole or any component of the formulation; pregnancy. Use in patients <18 years of age; premenopausal endocrine status; breastfeeding.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Adverse Effects    | Headache, nausea, peripheral edema, fatigue, hot flushes. Cardiovascular: Edema (7.2% to 18.4% ) Dermatologic: Hot sweats (5% to 49.7% ), Sweating (up to 24.2% ) Gastrointestinal: Constipation (1.5% to 11.3% ), Diarrhea (5% to 8% ), Loss of appetite (3% to 5% ), Nausea (8.6% to 17% ), Vomiting (2.7% to 7% ) Musculoskeletal: Arthralgia (8% to 22% ), Arthritis (6.7% to 21.1%), Backache (5% to 18% ), Bone pain (22% ), Myalgia (6.4% to 6.7% ) Neurologic: Asthenia (4% to 33.6% ), Dizziness (2.4% to 14.2% .), Headache (3.5% to 20.1% ), Insomnia (5.8% to 7% .), Somnolence (2% to 3% .) Respiratory: Dyspnea (5.5% to 18% ) Other: Fatigue (6% to 13% ) |
| Pregnancy          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Lactation          | Contraindicated                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

